ATI RN
ATI Pharmacology
1. A client is receiving daily doses of Oprelvekin. Which of the following laboratory values should be monitored to determine the effectiveness of this medication?
- A. Hemoglobin
- B. Absolute neutrophil count
- C. Platelet count
- D. Total white blood cell count
Correct answer: C
Rationale: Oprelvekin is a medication that stimulates platelet production. Therefore, monitoring the platelet count is essential to assess the effectiveness of this drug. The expected outcome for oprelvekin therapy is a platelet count greater than 50,000/mm^3. Changes in platelet count can indicate the response to the medication and help in adjusting the treatment plan accordingly. Monitoring hemoglobin, absolute neutrophil count, or total white blood cell count is not directly related to the mechanism of action of Oprelvekin and therefore would not provide accurate information on the drug's effectiveness.
2. A drug ending in the suffix (navir) is considered a ______.
- A. Antidepressant
- B. Protease inhibitor
- C. Beta antagonist
- D. H antagonist
Correct answer: B
Rationale: When a drug name ends in the suffix -navir, it indicates that the drug is a protease inhibitor. Protease inhibitors are commonly used in antiviral therapy to treat infections by inhibiting viral replication. Therefore, the correct answer is B: Protease inhibitor.
3. What is a desired outcome of the drug Phenytoin?
- A. Decrease symptoms of PTSD
- B. Resolution of signs of infection
- C. Decrease or cessation of seizures without excessive sedation
- D. Prevention or relief of bronchospasm
Correct answer: C
Rationale: The correct answer is C: Decrease or cessation of seizures without excessive sedation. Phenytoin is primarily used as an antiepileptic medication to manage and prevent seizures. It does not directly impact symptoms of PTSD (Choice A), resolution of signs of infection (Choice B), or prevention or relief of bronchospasm (Choice D). Therefore, the desired outcome of Phenytoin is to control seizures effectively while avoiding excessive sedation.
4. Which of the following is the antidote for benzodiazepine toxicity?
- A. Flumazenil
- B. Methylene blue
- C. Deferoxamine
- D. Alkalinize urine
Correct answer: A
Rationale: Flumazenil is the specific antidote for benzodiazepine toxicity. It acts as a competitive antagonist at the benzodiazepine binding site on the GABA receptor, reversing the sedative effects of benzodiazepines. Administration of flumazenil is indicated in cases of benzodiazepine overdose or toxicity to rapidly reverse the central nervous system depression caused by these drugs. It is important to note that flumazenil should be used cautiously in patients with a history of seizures or those who are physically dependent on benzodiazepines, as it can precipitate withdrawal symptoms or seizures.
5. What nursing interventions should you perform when a patient is on Albuterol? (Select all that apply)
- A. Assess lung sounds, pulse, and blood pressure before administering
- B. Monitor for changes in behavior
- C. Observe for paradoxical bronchospasms
- D. Both A and C
Correct answer: D
Rationale: The correct nursing interventions to perform when a patient is on Albuterol include assessing the patient's lung sounds, pulse, and blood pressure before administering the medication to monitor for cardiovascular side effects like increased heart rate. Additionally, it is crucial to observe for paradoxical bronchospasms, a rare but serious adverse reaction where the medication causes a worsening of bronchospasm instead of relief. Monitoring for changes in behavior is not directly related to Albuterol administration and is not a standard nursing intervention for patients receiving this medication, making choice B incorrect. Therefore, the correct answer is D as it includes the essential nursing actions for patients on Albuterol.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access